Journal of Hepatology
Volume 51, Issue 1 , Pages 1-3 , July 2009

Treatment with nucleos(t)ide analogues in chronic hepatitis B: Where does the road map lead us?

References 

  1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97–107
  2. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73
  3. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686
  4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242
  5. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003;37:748–755
  6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005;352:2673–2681
  7. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 2000;32:803–806
  8. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  9. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol. 2007;5:890–897
  10. Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int. 2009;29:108–115
  11. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;357:2576–2588
  12. Locarnini S, Qi X, Arterburn S, Snow A, Brosgart C, Currie G, et al. Incidence and predictors of emergence of adefovir resistant HBV during 4 years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) (abstract). J Hepatol. 2005;42:17
  13. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001;34:785–791
  14. Zeuzem S, Gane E, Liaw Y-F, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and on-treatment response predict the outcomes of 2 years telbivudine treatment of chronic hepatitis B. J Hepatol. 2009;51:11–20
  15. Heathcote EJ, Gane E, De Man R, Chan S, Sievert W, Mauss S, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis. Hepatology. 2008;48:A158
  16. Marcellin P, Buti M, Krastev Z, Gurel S, Balabanska R, Dusheiko G, et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (study 102), preliminary analysis. Hepatology. 2008;48:A146
  17. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009. [Epub ahead of print].
  18. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007;46:1695–1703
  19. Snow A, Chappell B, Curtis M, Zhu Y, Heathcote EJ, Marcellin P, et al. Week 96 resistance surveillance for HBeAg-positive and negative subjects with chronic HBV infection randomized to receive tenofovir DF 300mg QD. Hepatology. 2008;48:A977
  20. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-l-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001;12:119–129
  21. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009;136:486–495
  22. Lampertico P, Vigano M, Facchetti F, Puoti M, Minola E, Suter F, et al. Effectiveness of entecavir for the treatment of NUC-naive chronic hepatitis B patients: a large multicenter cohort study in clinical practice. Hepatology. 2008;48:A896
  23. Reijnders JGP, Deterding K, Petersen J, Zoulim F, Santantonio T, Buti M, et al. Antiviral effect of entecavir: results from 160 chronic hepatitis B patients in an international multicenter cohort study. In: The 44th annual meeting of the European Association for the Study of the Liver (EASL). Copenhagen, Denmark 2009.
  24. Van Bommel F, De Man R, Stein K, Huppe D, Petersen J, Buggisch P, et al. A multicenter analysis of antiviral response after one year of tenofovir monotherapy in HBV-monoinfected patients with prior nucleos(t)ide analog experience. J Hepatol. 2008;48:A73

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00259-1

doi: 10.1016/j.jhep.2009.04.007

Journal of Hepatology
Volume 51, Issue 1 , Pages 1-3 , July 2009

Article Tools